Updates in Psoriasis Treatment: New Data From Vienna

Plaque psoriasis is a debilitating, noncurable autoimmune disorder, having a significant impact on quality of life, associated with depression, anxiety, social isolation, unemployment, and suicide. Various therapies, such as topical formulations and phototherapy, are currently available. The latest breakthroughs in understanding the immunopathology underlying plaque psoriasis include the identification of interleukins (IL-17, IL-22, and IL-23), which drive the chronic inflammatory nature of the disease. Multiple types of therapies in several drug classes are available and more are in the pipeline. In this Rapid Response activity, the latest evidence from the 2016 European Academy of Dermatology and Venereology Congress meeting on the efficacy and safety of new and emerging therapies for plaque psoriasis will be examined.
 
Educational Partner: Vindico Medical Education

Medium: Online Presentation

Commerical Support: This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Learning Objectives and Target Audience

Upon completion of this activity, participants will be able to:

  • Examine new evidence regarding treatment selection for plaque psoriasis based on disease severity and how the mechanisms of action of new and emerging therapies target the immunological pathways of the disease;
  • Analyze the latest efficacy data of new and emerging therapies for plaque psoriasis, including small-molecule inhibitors and immunotherapy;
  • Evaluate the latest safety data pertaining to the use of immunotherapy in the treatment of plaque psoriasis to assist in the development of strategies to prevent, recognize, and effectively manage potential adverse effects.
The intended audience for the activity is dermatology physicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with psoriasis.
Additional information
ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Email: 
Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
11/08/2016
Activity expires: 
11/08/2017
ACTIVITY CHAIR
  Andrew Blauvelt, MD, MBA
  President
  Oregon Medical Research Center
  Portland, OR
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nurses and other healthcare professionals will receive a Certificate of Participation.  For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Accreditation Period

Activity opens: 
11/08/2016
Activity expires: 
11/08/2017
Registration: To view this activity, you will need to visit the Open CME website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!
 
Please login or create an account to take this course.